- Home
- IMCC vs VYNE Comparison
IMCC vs VYNE Comparison
Compare IMCC & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- VYNE
- Stock Information
- Founded
- IMCC 1980
- VYNE 2003
- Country
- IMCC Israel
- VYNE United States
- Employees
- IMCC N/A
- VYNE N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- VYNE Health Care
- Exchange
- IMCC Nasdaq
- VYNE Nasdaq
- Market Cap
- IMCC 10.4M
- VYNE 12.3M
- IPO Year
- IMCC N/A
- VYNE 2018
- Fundamental
- Price
- IMCC $1.32
- VYNE $0.36
- Analyst Decision
- IMCC
- VYNE Buy
- Analyst Count
- IMCC 0
- VYNE 2
- Target Price
- IMCC N/A
- VYNE $8.00
- AVG Volume (30 Days)
- IMCC 1.3M
- VYNE 1.8M
- Earning Date
- IMCC 11-13-2025
- VYNE 11-06-2025
- Dividend Yield
- IMCC N/A
- VYNE N/A
- EPS Growth
- IMCC N/A
- VYNE N/A
- EPS
- IMCC N/A
- VYNE N/A
- Revenue
- IMCC $37,606,703.00
- VYNE $524,000.00
- Revenue This Year
- IMCC $47.12
- VYNE N/A
- Revenue Next Year
- IMCC $12.83
- VYNE N/A
- P/E Ratio
- IMCC N/A
- VYNE N/A
- Revenue Growth
- IMCC 1.92
- VYNE 6.29
- 52 Week Low
- IMCC $0.93
- VYNE $0.28
- 52 Week High
- IMCC $7.12
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- IMCC 43.09
- VYNE 49.45
- Support Level
- IMCC $0.93
- VYNE $0.35
- Resistance Level
- IMCC $1.54
- VYNE $0.40
- Average True Range (ATR)
- IMCC 0.16
- VYNE 0.03
- MACD
- IMCC 0.01
- VYNE 0.00
- Stochastic Oscillator
- IMCC 60.33
- VYNE 53.03
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.